Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rodinò

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Expert Opinion on Biological Therapy|January 22, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.
Journal of Clinical Medicine|November 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.
Journal of Clinical Medicine|December 17, 2024
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Expert Opinion on Biological Therapy|December 14, 2021
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in ItalyAntonio Tursi, Giammarco Mocci, Leonardo Allegretta, et al.
Expert Opinion on Pharmacotherapy|June 26, 2023
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world studyAntonio Tursi, Giammarco Mocci, Linda Cingolani, et al.
Expert Opinion on Biological Therapy|January 22, 2024
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life studyAntonio Tursi, Giammarco Mocci, Franco Scaldaferri, et al.
Journal of Clinical Medicine|November 13, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.
Journal of Clinical Medicine|December 17, 2024
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort StudyGiammarco Mocci, Antonio Tursi, Franco Scaldaferri, et al.
Pageof 2